Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: A study of 157 patients

Anti-Cancer Drugs

Volumn 24, Issue 6, 2013, Pages 623-629

  Fayette, Jérôme ^a   Bonnin, Nathalie ^a   Ferlay, Céline ^a   Lallemant, Benjamin ^b   Ramade, Antoine ^a   Favrel, Véronique ^a   Zrounba, Philippe ^a   Chabaud, Sylvie ^a   Pommier, Pascal ^a   Poupart, Marc ^a   Céruse, Philippe ^a  

^a UNIVERSITÉ DE LYON   (France)

^b NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

cetuximab; chemoradiation; cisplatin; docetaxel; head and neck cancer; induction; potentiation; TPF

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NEUTROPENIA; ORGAN PRESERVATION; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84878942237     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328360b9d6     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Saunders MI, Rojas AM. Management of cancer of the head and neck - a cocktail with your PORT? N Engl J Med 2004; 350:1997-1999. (Pubitemid 38580204)
3. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328:184-194.
4. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091-2098. (Pubitemid 37464533)
5. Forastiere AA, Maor M,Weber RS, Pajak T, Glisson B, Trotti A, et al. Longterm results of intergroup RTOG 91-11: a phase III trial to preserve the larynx - induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy [abstract]. J Clin Oncol 2006; 24:5517.
6. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357:1695-1704. (Pubitemid 350005151)
7. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101:498-506.
8. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-1715. (Pubitemid 350005152)
9. McGhie JEW, LRC Program. Network meta-analysis (MA) of taxane-based neoadjuvant chemotherapy (NCT) for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) [abstract]. J Clin Oncol 2010; 28:5568.
10. Paccagnella A, Ghi MG, Loreggian L, Buffoli A, Koussis H, Mione CA, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010; 21:1515-1522.
11. Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia Giron C, Irigoyen A, et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU followed by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC) [abstract]. J Clin Oncol 2009; 27:6009.
12. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952. (Pubitemid 38580197)
13. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937-1944.
14. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. (Pubitemid 43209104)
15. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92:4-14.
16. Sobin L, Gospodarowicz M, Wittekind C. Head and neck tumours. UICC International Union Against Cancer-TNM classification of malignant tumours. Hoboken, NJ: Wiley-Blackwell; 2010.
17. Racadot S, Mercier M, Dussart S, Dessard-Diana B, Bensadoun RJ, Martin M, et al. Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement. Radiother Oncol 2008; 87:164-172.
18. Lefebvre J, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study [abstract]. J Clin Oncol 2009; 27:6010.
19. Lefebvre J, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): results of the randomized phase II TREMPLIN study [abstract]. Clin Oncol 2011; 29:5501.
20. Forastiere AA, Zhang Q,Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2012 (in press).
21. Haddad RI, Rabinowits G, Tishler RB, Adkins D, Raja Khuri F, Clark J, et al. The PARADIGM trial: a phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC) [abstract]. J Clin Oncol 2012; 30:5501.
22. Cohen EEW, Karrison T, Kocherginsky M, Huang CH, Agulnik M, Bhushan Mittal B, et al. DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2012; 30:5500.
23. Adelstein DJ, Li Y, Adams GL, Wagner HJ, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21:92-98.
24. Ensley JF, Jacobs JR, Weaver A, Kinzie J, Crissman J, Kish JA, et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984; 54:811-814. (Pubitemid 14058432)